Teleflex Announces Publication of Early Patient Experience Data Highlighting the UroLift System as a Superior Treatment to Rezum Steam Injection in Patients with Enlarged Prostate

Data Shows Minimally Invasive Treatment Provides Rapid Symptom Relief, Allowing Men to Return to Daily Activities Quickly

WAYNE, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of data from a study comparing patient experience of those treated with the UroLift System for benign prostatic hyperplasia (BPH) to those who received the Rezum steam injection. Results highlighting early positive experience following treatment with the UroLift System were published in the Canadian Journal of Urology.

“These published results further emphasize the unique benefits of the minimally invasive UroLift System for men dealing with the burdensome symptoms of BPH,” said Dave Amerson, president of Teleflex Interventional Urology business unit. “Not only does the UroLift System provide durable and lasting symptom relief, but it also allows men to return to a better quality of life. We are pleased to see that these results highlight the distinct advantages of the UroLift System compared to other minimally invasive treatments and that they are consistent to those seen in past clinical studies, demonstrating preservation of sexual function, rapid return to daily activities and high patient satisfaction among patients treated with the UroLift System.”

The study compared 53 non-retention patients from two U.S. sites who received treatment with either the UroLift System or tissue ablation with the Rezum steam injection. To report the early postoperative patient experience, the study measured symptom response, catheterization rates, and recovery and satisfaction at up to two months post-treatment.  

Early post-operative results from the study showed positive differences for patients treated with the UroLift System compared to Rezum, including better sexual function outcomes, less interference in daily activities and higher patient satisfaction following the procedure. Additionally, results from the study found more than twice as many patients who received the UroLift System treatment reported being catheter free at day three (93%) compared to those who received Rezum (45%). At the 30-day mark, absolute symptom score was 45% better among patients treated with the UroLift System compared to those treated with Rezum.